Personalized medicine is gaining popularity as patients worldwide realize the benefits being actively involved in their own treatment. Telemedicine is a viable option for such patients.
Helping such patients, SHL Telemedicine has announced that its subscribers were at low risk of hospital readmission when they suffered from acute myocardial infarction (AMI). The company was referring to a study conducted by the Departments of Cardiology and Internal Medicine at Tel Aviv University to support its claims.
The study showed that SHL Telemedicine subscribers experienced a 5.8 percent hospital readmission rate after being hospitalized for AMI. The study evaluated 897 patients and only 52 patients, or 5.8 percent, were readmitted to the hospital. These are impressive numbers since in the U.S. alone, about 720,000 patients have an MI contributing to approximately 935,000 hospitalizations.
SHL Telemedicine primarily caters to people who need home medicine and who are not able to go to pharmacies. The company provides immediate and professional medical care when the patients need it.
“Our telemedicine platform enables patients to have greater control over their heart conditions by successfully monitoring heart beat irregularities and notifying the patient as to when medical consultation is required. In turn, our solution also reassures patients when no treatment is necessary," explained Erez Alroy, co-CEO of SHL Telemedicine. "The results from this study demonstrate that our telemedicine platform empowers patients to better manage their medical care. This significantly reduces unnecessary hospital readmissions, resulting in substantial cost savings to the medical community and greatly improving quality of life for patients”
According to reports, more than 200 million people in the EU and the U.S. suffer from one or several diseases where they need home medicines. Companies like SHL Telemedicine also help patients who want to monitor their health without the help of doctors or hospitals.